Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Esomeprazole + loxoprofen is a **fixed-dose combination** medication consisting of two active pharmaceutical ingredients: **esomeprazole**, a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase (proton pump) in gastric parietal cells, and **loxoprofen**, a nonsteroidal anti-inflammatory drug (NSAID) that provides analgesic, anti-inflammatory, and antipyretic effects primarily by inhibiting cyclooxygenase (COX) enzymes and thereby reducing prostaglandin synthesis. This combination is designed to provide relief from pain and inflammation (as seen in musculoskeletal and arthritic conditions) while reducing the risk of NSAID-induced gastric ulcers and upper gastrointestinal complications by co-administering a gastroprotective agent (esomeprazole). This combination is similar in rationale to approved fixed-dose combinations of esomeprazole with other NSAIDs (e.g., naproxen) used in arthritis and musculoskeletal disorders, but as of this writing, there is **no evidence of an approved or widely marketed fixed-dose product specifically combining esomeprazole and loxoprofen**. Loxoprofen is commonly used in East Asian countries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on esomeprazole + loxoprofen.